Practical combination therapy based on pathophysiology of type 2 diabetes

References

• International Diabetes Federation, Global burden Sixth edition 2014 Available from: http://www.idf.org/diabetesatlas/5e/the-global-burden Accessed February 9, 2015
   Google Scholar
• Kahn SE Cooper ME Del Prato S Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future Lancet 2014 383 9922 1068 1083 24315620
   PubMed Web of Science ®Google Scholar
• Garber AJ Abrahamson MJ Barzilay JI Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm - 2016 executive summary Endocr Pract 2016 22 1 84 113 26731084
   PubMed Web of Science ®Google Scholar
• American Diabetes Association 7. Approaches to glycemic treatment Diabetes Care 2016 39 Suppl 1 S52 S59 26696682
   PubMed Web of Science ®Google Scholar
• Berkowitz SA Krumme AA Avorn J Initial choice of oral glucose-lowering medication for diabetes mellitus: a patient-centered comparative effectiveness study JAMA Intern Med 2014 174 12 1955 1962 25347323
   PubMed Web of Science ®Google Scholar
• Khunti K Wolden ML Thorsted BL Andersen M Davies MJ Clinical inertia in people with type 2 diabetes: a retrospective cohort study of more than 80,000 people Diabetes Care 2013 36 11 3411 3417 23877982
   PubMed Web of Science ®Google Scholar
• Levin PA Wei W Zhou S Xie L Baser O Outcomes and treatment patterns of adding a third agent to 2 OADs in patients with type 2 diabetes J Manag Care Spec Pharm 2014 20 5 501 512 24761822
   PubMed Web of Science ®Google Scholar
• Brown JB Nichols GA Perry A The burden of treatment failure in type 2 diabetes Diabetes Care 2004 27 7 1535 1540 15220224
   PubMed Web of Science ®Google Scholar
• Garber AJ Abrahamson MJ Barzilay JI American Association of Clinical Endocrinologists’ comprehensive diabetes management algorithm 2013 consensus statement–executive summary Endocr Pract 2013 19 3 536 557 23816937
   PubMed Web of Science ®Google Scholar
• DeFronzo RA Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus Diabetes 2009 58 4 773 795 19336687
   PubMed Web of Science ®Google Scholar
• Triplitt CL Examining the mechanisms of glucose regulation Am J Manag Care 2012 18 1 suppl S4 S10 22559855
   PubMedGoogle Scholar
• Ravnskjaer K Hogan MF Lackey D Glucagon regulates gluconeogenesis through KAT2B- and WDR5-mediated epigenetic effects J Clin Invest 2013 123 10 4318 4328 24051374
   PubMed Web of Science ®Google Scholar
• Triplitt C Understanding the kidney’s role in blood glucose regulation Am J Manag Care 2012 18 S11 S16 22559853
   PubMedGoogle Scholar
• Gerich JE Meyer C Woerle HJ Stumvoll M Renal gluconeogenesis: its importance in human glucose homeostasis Diabetes Care 2001 24 2 382 391 11213896
   PubMed Web of Science ®Google Scholar
• Basu R Chandramouli V Dicke B Landau B Rizza R Obesity and type 2 diabetes impair insulin-induced suppression of glycogenolysis as well as gluconeogenesis Diabetes 2005 54 7 1942 1948 15983193
   PubMed Web of Science ®Google Scholar
• Barthel A Schmoll D Novel concepts in insulin regulation of hepatic gluconeogenesis Am J Physiol Endocrinol Metab 2003 285 4 E685 E692 12959935
   PubMed Web of Science ®Google Scholar
• Guilherme A Virbasius JV Puri V Czech MP Adipocyte dysfunctions linking obesity to insulin resistance and type 2 diabetes Nat Rev Mol Cell Biol 2008 9 5 367 377 18401346
   PubMed Web of Science ®Google Scholar
• Wellen KE Hotamisligil GS Inflammation, stress, and diabetes J Clin Invest 2005 115 5 1111 1119 15864338
   PubMed Web of Science ®Google Scholar
• Wensveen FM Valentic S Sestan M Turk Wensveen T Polic B The “Big Bang” in obese fat: Events initiating obesity-induced adipose tissue inflammation Eur J Immunol 2015 45 9 2446 2456 26220361
   PubMed Web of Science ®Google Scholar
• Xu H Barnes GT Yang Q Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance J Clin Invest 2003 112 12 1821 1830 14679177
   PubMed Web of Science ®Google Scholar
• Weisberg SP McCann D Desai M Rosenbaum M Leibel RL Ferrante AWJr Obesity is associated with macrophage accumulation in adipose tissue J Clin Invest 2003 112 12 1796 1808 14679176
   PubMed Web of Science ®Google Scholar
• Poitout V Robertson RP Glucolipotoxicity: fuel excess and beta-cell dysfunction Endocr Rev 2008 29 3 351 366 18048763
   PubMed Web of Science ®Google Scholar
• Russo GT Giorda CB Cercone S Nicolucci A Cucinotta D BetaDecline Study Group Factors associated with beta-cell dysfunction in type 2 diabetes: the BETADECLINE study PLoS One 2014 9 10 e109702 25347846
   PubMed Web of Science ®Google Scholar
• DeFronzo RA Tripathy D Skeletal muscle insulin resistance is the primary defect in type 2 diabetes Diabetes Care 2009 32 suppl 2 S157 S163 19875544
   PubMed Web of Science ®Google Scholar
• Cnop M Vidal J Hull RL Progressive loss of beta-cell function leads to worsening glucose tolerance in first-degree relatives of subjects with type 2 diabetes Diabetes Care 2007 30 3 677 682 17327340
   PubMed Web of Science ®Google Scholar
• Hu FB van Dam RM Liu S Diet and risk of Type II diabetes: the role of types of fat and carbohydrate Diabetologia 2001 44 7 805 817 11508264
   PubMed Web of Science ®Google Scholar
• Guenard F Deshaies Y Cianflone K Kral JG Marceau P Vohl MC Differential methylation in glucoregulatory genes of offspring born before vs. after maternal gastrointestinal bypass surgery Proc Natl Acad Sci U S A 2013 110 28 11439 11444 23716672
   PubMed Web of Science ®Google Scholar
• Nauck MA Baller B Meier JJ Gastric inhibitory polypeptide and glucagon-like peptide-1 in the pathogenesis of type 2 diabetes Diabetes 2004 53 suppl 3 S190 S196
   Web of Science ®Google Scholar
• Drucker DJ The biology of incretin hormones Cell Metab 2006 3 3 153 165 16517403
   PubMed Web of Science ®Google Scholar
• Drucker DJ Nauck MA The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes Lancet 2006 368 9548 1696 1705 17098089
   PubMed Web of Science ®Google Scholar
• Drucker DJ Sherman SI Gorelick FS Bergenstal RM Sherwin RS Buse JB Incretin-based therapies for the treatment of type 2 diabetes: evaluation of the risks and benefits Diabetes Care 2010 33 2 428 433 20103558
   PubMed Web of Science ®Google Scholar
• Nauck MA Heimesaat MM Orskov C Holst JJ Ebert R Creutzfeldt W Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus J Clin Invest 1993 91 1 301 307 8423228
   PubMed Web of Science ®Google Scholar
• Nauck MA Vardarli I Deacon CF Holst JJ Meier JJ Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down? Diabetologia 2011 54 1 10 18 20871975
   PubMed Web of Science ®Google Scholar
• Nauck MA Update on developments with SGLT2 inhibitors in the management of type 2 diabetes Drug Des Devel Ther 2014 8 1335 1380
   PubMed Web of Science ®Google Scholar
• Meyer C Woerle HJ Dostou JM Welle SL Gerich JE Abnormal renal, hepatic, and muscle glucose metabolism following glucose ingestion in type 2 diabetes Am J Physiol Endocrinol Metab 2004 287 6 E1049 E1056 15304374
   PubMed Web of Science ®Google Scholar
• Abdul-Ghani MA Norton L Defronzo RA Role of sodium-glucose cotransporter 2 (SGLT 2) inhibitors in the treatment of type 2 diabetes Endocr Rev 2011 32 4 515 531 21606218
   PubMed Web of Science ®Google Scholar
• Murphy KG Bloom SR Gut hormones in the control of appetite Exp Physiol 2004 89 5 507 516 15184357
   PubMed Web of Science ®Google Scholar
• Thaler JP Schwartz MW Minireview: Inflammation and obesity pathogenesis: the hypothalamus heats up Endocrinology 2010 151 9 4109 4115 20573720
   PubMed Web of Science ®Google Scholar
• Thaler JP Yi CX Schur EA Obesity is associated with hypothalamic injury in rodents and humans J Clin Invest 2012 122 1 153 162 22201683
   PubMed Web of Science ®Google Scholar
• Shi SQ Ansari TS McGuinness OP Wasserman DH Johnson CH Circadian disruption leads to insulin resistance and obesity Curr Biol 2013 23 5 372 381 23434278
   PubMed Web of Science ®Google Scholar
• Gale JE Cox HI Qian J Block GD Colwell CS Matveyenko AV Disruption of circadian rhythms accelerates development of diabetes through pancreatic beta-cell loss and dysfunction J Biol Rhythms 2011 26 5 423 433 21921296
   PubMed Web of Science ®Google Scholar
• Viollet B Guigas B Sanz Garcia N Leclerc J Foretz M Andreelli F Cellular and molecular mechanisms of metformin: an overview Clin Sci (Lond) 2012 122 6 253 270 22117616
   PubMed Web of Science ®Google Scholar
• Wang CC Lin SK Tseng YF Elevation of serum aminotransferase activity increases risk of carotid atherosclerosis in patients with non-alcoholic fatty liver disease J Gastroenterol Hepatol 2009 24 8 1411 1416 19702910
   PubMed Web of Science ®Google Scholar
• Idilman R Mizrak D Corapcioglu D Clinical trial: insulin-sensitizing agents may reduce consequences of insulin resistance in individuals with non-alcoholic steatohepatitis Aliment Pharmacol Ther 2008 28 2 200 208 18445142
   PubMed Web of Science ®Google Scholar
• Facciorusso A The influence of diabetes in the pathogenesis and the clinical course of hepatocellular carcinoma: recent findings and new perspectives Curr Diabetes Rev 2013 9 5 382 386 23845075
   PubMedGoogle Scholar
• Singh S Singh PP Singh AG Murad MH Sanchez W Anti-diabetic medications and the risk of hepatocellular cancer: a systematic review and meta-analysis Am J Gastroenterol 2013 108 6 881 891 quiz 892 23381014
   PubMed Web of Science ®Google Scholar
• Zhao D Shi Z Warriner AH Molecular mechanism of thiazolidinedione-mediated inhibitory effects on osteoclastogenesis PLoS One 2014 9 7 e102706 25032991
   PubMed Web of Science ®Google Scholar
• Miyazaki Y Mahankali A Matsuda M Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone Diabetes Care 2001 24 4 710 719 11315836
   PubMed Web of Science ®Google Scholar
• Miyazaki Y Matsuda M DeFronzo RA Dose-response effect of pioglitazone on insulin sensitivity and insulin secretion in type 2 diabetes Diabetes Care 2002 25 3 517 523 11874940
   PubMed Web of Science ®Google Scholar
• Miyazaki Y Glass L Triplitt C Effect of rosiglitazone on glucose and non-esterified fatty acid metabolism in Type II diabetic patients Diabetologia 2001 44 12 2210 2219 11793023
   PubMed Web of Science ®Google Scholar
• American Diabetes Association Standards of Medical Care in Diabetes-2016 Diabetes Care 2016 39 Suppl 1 S1 S119 26696671
   PubMed Web of Science ®Google Scholar
• Proks P Reimann F Green N Gribble F Ashcroft F Sulfonylurea stimulation of insulin secretion Diabetes 2002 51 suppl 3 S368 S376 12475777
   PubMed Web of Science ®Google Scholar
• Aquilante CL Sulfonylurea pharmacogenomics in type 2 diabetes: the influence of drug target and diabetes risk polymorphisms Expert Rev Cardiovasc Ther 2010 8 3 359 372 20222815
   PubMedGoogle Scholar
• Reis AF Velho G Sulfonylurea receptor -1 (SUR1): genetic and metabolic evidences for a role in the susceptibility to type 2 diabetes mellitus Diabetes Metab 2002 28 1 14 19 11938023
   PubMed Web of Science ®Google Scholar
• Handelsman Y Bloomgarden ZT Grunberger G American Association of Clinical Endocrinologists and American College of Endocrinology clinical practice guidelines for developing a diabetes mellitus comprehensive care plan-2015 Endocr Pract 2015 21 suppl 1 1 87
   PubMed Web of Science ®Google Scholar
• Baggio L Drucker DJ Biology of incretins: GLP-1 and GIP Gastroenterology 2007 132 2131 2157 17498508
   PubMed Web of Science ®Google Scholar
• Deacon CF Johnsen AH Holst JJ Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo J Clin Endocrinol Metab 1995 80 3 952 957 7883856
   PubMed Web of Science ®Google Scholar
• Nauck MA El-Ouaghlidi A The therapeutic actions of DPP-IV inhibition are not mediated by glucagon-like peptide-1 Diabetologia 2005 48 4 608 611 15761719
   PubMed Web of Science ®Google Scholar
• Baetta R Corsini A Pharmacology of dipeptidyl peptidase-4 inhibitors: similarities and differences Drugs 2011 71 11 1441 1467 21812507
   PubMed Web of Science ®Google Scholar
• He K Shi JC Mao XM Safety and efficacy of acarbose in the treatment of diabetes in Chinese patients Ther Clin Risk Manag 2014 10 505 511 25061309
   PubMed Web of Science ®Google Scholar
• Zhu Q Tong Y Wu T Li J Tong N Comparison of the hypoglycemic effect of acarbose monotherapy in patients with type 2 diabetes mellitus consuming an Eastern or Western diet: a systematic meta-analysis Clin Ther 2013 35 6 880 899 23602502
   PubMed Web of Science ®Google Scholar
• Holt RI Barnett AH Bailey CJ Bromocriptine: old drug, new formulation and new indication Diabetes Obes Metab 2010 12 12 1048 1057 20977575
   PubMed Web of Science ®Google Scholar
• Handelsman Y Role of bile acid sequestrants in the treatment of type 2 diabetes Diabetes Care 2011 34 suppl 2 S244 S250 21525463
   PubMed Web of Science ®Google Scholar
• Beysen C Murphy EJ Deines K Effect of bile acid sequestrants on glucose metabolism, hepatic de novo lipogenesis, and cholesterol and bile acid kinetics in type 2 diabetes: a randomised controlled study Diabetologia 2012 55 2 432 442 22134839
   PubMed Web of Science ®Google Scholar
• Lantus® (insulin glargine [rDNA origin] injection). [prescribing information] Bridgewater, NJ sanofiaventis 2009
   Google Scholar
• Levemir® (insulin detemir) [prescribing information] Bagsvaerd, Denmark Novo Nordisk A/S 2015
   Google Scholar
• Tresiba® (insulin degludec injection) [prescribing information] Bagsvaerd, Denmark Novo Nordisk A/S 2015
   Google Scholar
• Toujeo® (insulin glargine) [prescribing Information] Summary of Product Characteristics Frankfurt, Germany Sanofi-Aventis Deutschland, GmbH 2015
   Google Scholar
• Sanofi Press Release: Sanofi reports positive phase 3 results for Toujeo^® (insulin glargine [rDNA origin] injection, 300 U/mL) 2015 Available from: http://www.news.sanofi.us/2014-06-14-Sanofi-Reports-Positive-Phase-3-Results-for-Toujeo-insulin-glargine-rDNA-origin-injection-300-U-mL Accessed December 7, 2015
   Google Scholar
• Hallsten K Virtanen KA Lonnqvist F Rosiglitazone but not metformin enhances insulin- and exercise-stimulated skeletal muscle glucose uptake in patients with newly diagnosed type 2 diabetes Diabetes 2002 51 12 3479 3485 12453903
   PubMed Web of Science ®Google Scholar
• Malin SK Gerber R Chipkin SR Braun B Independent and combined effects of exercise training and metformin on insulin sensitivity in individuals with prediabetes Diabetes Care 2012 35 1 131 136 22040838
   PubMed Web of Science ®Google Scholar
• Graham GG Punt J Arora M Clinical pharmacokinetics of metformin Clin Pharmacokinet 2011 50 2 81 98 21241070
   PubMed Web of Science ®Google Scholar
• Glucophage® (metformin hydrochloride) and Glucophage XR® (metformin hydrochloride extended-release) [prescribing information] Princeton, NJ Bristol-Myers Squibb Company 2009
   Google Scholar
• Kim CH Han KA Oh HJ Safety, tolerability, and efficacy of metformin extended-release oral antidiabetic therapy in patients with type 2 diabetes: an observational trial in Asia J Diabetes 2012 4 4 395 406 22742083
   PubMed Web of Science ®Google Scholar
• Yu Y Li X Blanchard J Insulin sensitizers improve learning and attenuate tau hyperphosphorylation and neuroinflammation in 3xTg-AD mice J Neural Transm (Vienna) 2015 122 4 593 606 25113171
   PubMed Web of Science ®Google Scholar
• Genovese S De Berardis G Nicolucci A Effect of pioglitazone versus metformin on cardiovascular risk markers in type 2 diabetes Adv Ther 2013 30 2 190 202 23359066
   PubMed Web of Science ®Google Scholar
• Actos® (pioglitazone hydrochloride) [prescribing information] Deerfield, IL Takeda Pharmaceuticals America, Inc 2012
   Google Scholar
• Avandia® (rosiglitazone maleate) [prescribing information] Research Triangle Park, NC GlaxoSmithKline 2011
   Google Scholar
• Amin M Suksomboon N Pharmacotherapy of type 2 diabetes mellitus: an update on drug-drug interactions Drug Saf 2014 37 11 903 919 25249046
   PubMed Web of Science ®Google Scholar
• Reid T Choosing GLP-1 receptor agonists or DPP-4 inhibitors: weighing the clinical trial evidence Clin Diabetes 2012 30 1 3 12
   Google Scholar
• Mulherin AJ Oh AH Kim H Grieco A Lauffer LM Brubaker PL Mechanisms underlying metformin-induced secretion of glucagon-like peptide-1 from the intestinal L cell Endocrinology 2011 152 12 4610 4619 21971158
   PubMed Web of Science ®Google Scholar
• Migoya EM Bergeron R Miller JL Dipeptidyl peptidase-4 inhibitors administered in combination with metformin result in an additive increase in the plasma concentration of active GLP-1 Clin Pharmacol Ther 2010 88 6 801 808 21048706
   PubMed Web of Science ®Google Scholar
• Cuthbertson J Patterson S O’Harte FP Bell PM Addition of metformin to exogenous glucagon-like peptide-1 results in increased serum glucagon-like peptide-1 concentrations and greater glucose lowering in type 2 diabetes mellitus Metabolism 2011 60 1 52 56 20152998
   PubMed Web of Science ®Google Scholar
• Kahn SE Lachin JM Zinman B Effects of rosiglitazone, glyburide, and metformin on beta-cell function and insulin sensitivity in ADOPT Diabetes 2011 60 5 1552 1560 21415383
   PubMed Web of Science ®Google Scholar
• Del Guerra S Marselli L Lupi R Effects of prolonged in vitro exposure to sulphonylureas on the function and survival of human islets J Diabetes Complications 2005 19 1 60 64 15642492
   PubMed Web of Science ®Google Scholar
• Maedler K Carr RD Bosco D Zuellig RA Berney T Donath MY Sulfonylurea induced beta-cell apoptosis in cultured human islets J Clin Endocrinol Metab 2005 90 1 501 506 15483097
   PubMed Web of Science ®Google Scholar
• Campbell IW Mariz S Beta-cell preservation with thiazolidinediones Diabetes Res Clin Pract 2007 76 2 163 176 17052795
   PubMed Web of Science ®Google Scholar
• Vilsboll T The effects of glucagon-like peptide-1 on the beta cell Diabetes Obes Metab 2009 11 suppl 3 11 18 19878257
   PubMed Web of Science ®Google Scholar
• Garber AJ Incretin effects on beta-cell function, replication, and mass: the human perspective Diabetes Care 2011 34 Suppl 2 S258 S263 21525465
   PubMed Web of Science ®Google Scholar
• Garber A Henry R Ratner R Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial Lancet 2009 373 9662 473 481 18819705
   PubMed Web of Science ®Google Scholar
• Leibowitz G Cahn A Bhatt DL Impact of treatment with saxagliptin on glycaemic stability and beta-cell function in the SAVOR-TIMI 53 study Diabetes Obes Metab 2015 17 5 487 494 25656169
   PubMed Web of Science ®Google Scholar
• Merovci A Mari A Solis C Dapagliflozin lowers plasma glucose concentration and improves beta cell function J Clin Endocrinol Metab 2015 100 5 1927 1932 25710563
   PubMed Web of Science ®Google Scholar
• Fonseca V Effect of thiazolidinediones on body weight in patients with diabetes mellitus Am J Med 2003 115 suppl 8A 42S 48S 14678865
   PubMed Web of Science ®Google Scholar
• Shi H Moustaid-Moussa N Wilkison WO Zemel MB Role of the sulfonylurea receptor in regulating human adipocyte metabolism FASEB J 1999 13 13 1833 1838 10506587
   PubMed Web of Science ®Google Scholar
• Acarbose [prescribing information] Morgantown, WV Mylan Pharmaceuticals, Inc 2015
   Google Scholar
• Wang B Zhong J Lin H Blood pressure-lowering effects of GLP-1 receptor agonists exenatide and liraglutide: a meta-analysis of clinical trials Diabetes Obes Metab 2013 15 8 737 749 23433305
   PubMed Web of Science ®Google Scholar
• McGovern A Dutta N Watters K Munro N Feher M Additive weight loss effect with a combination of an oral sodium-glucose cotransporter 2 (SGLT2) inhibitor and a glucagon-like peptide 1 (GLP-1) agonist in type 2 diabetes. A6 (P143) Paper presented at: Diabetes UK Professional Conference March 11–13, 2015 London, UK
   Google Scholar
• Lewin A DeFronzo R Patel S Initial combination of empagliflozin and linagliptin in subjects with type 2 diabetes Diabetes Care 2015 38 3 394 402 25633662
   PubMed Web of Science ®Google Scholar
• Matthaei S Bowering K Rohwedder K Grohl A Parikh S Study 05 Group Dapagliflozin improves glycemic control and reduces body weight as add-on therapy to metformin plus sulfonylurea: a 24-week randomized, double-blind clinical trial Diabetes Care 2015 38 3 365 372 25592197
   PubMed Web of Science ®Google Scholar
• Liu SC Chien KL Wang CH Chen WC Leung CH Efficacy and safety of adding pioglitazone or sitagliptin to patients with type 2 diabetes insufficiently controlled with metformin and a sulfonylurea Endocr Pract 2013 1 30
   Web of Science ®Google Scholar
• DeFronzo RA Burant CF Fleck P Wilson C Mekki Q Pratley RE Efficacy and tolerability of the DPP-4 inhibitor alogliptin combined with pioglitazone, in metformin-treated patients with type 2 diabetes J Clin Endocrinol Metab 2012 97 5 1615 1622 22419732
   PubMed Web of Science ®Google Scholar
• Kovacs CS Seshiah V Swallow R Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial Diabetes Obes Metab 2014 16 2 147 158 23906415
   PubMed Web of Science ®Google Scholar
• Rosenstock J Hansen L Zee P Dual add-on therapy in type 2 diabetes poorly controlled with metformin monotherapy: a randomized double-blind trial of saxagliptin plus dapagliflozin addition versus single addition of saxagliptin or dapagliflozin to metformin Diabetes Care 2014 38 3 376 383 25352655
   PubMed Web of Science ®Google Scholar
• DeFronzo RA Lewin A Patel S Combination of empagliflozin and linagliptin as second-line therapy in subjects with type 2 diabetes inadequately controlled on metformin Diabetes Care 2015 38 3 384 393 25583754
   PubMed Web of Science ®Google Scholar
• Jabbour SA Hardy E Sugg J Parikh S Study 10 Group Dapagliflozin is effective as add-on therapy to sitagliptin with or without metformin: a 24-week, multicenter, randomized, double-blind, placebo-controlled study Diabetes Care 2014 37 3 740 750 24144654
   PubMed Web of Science ®Google Scholar
• Matthaei S Catrinoiu D Celinski A Randomized, double-blind trial of triple therapy with saxagliptin add-on to dapagliflozin plus metformin in patients with type 2 diabetes Diabetes Care 2015 38 11 2018 2024 26324329
   PubMed Web of Science ®Google Scholar
• Mathieu C Ranetti AE Li D Randomized, double-blind, phase 3 trial of triple therapy with dapagliflozin add-on to saxagliptin plus metformin in type 2 diabetes Diabetes Care 2015 38 11 2009 2017 26246458
   PubMed Web of Science ®Google Scholar
• Merovci A Solis-Herrera C Daniele G Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production J Clin Invest 2014 124 2 509 514 24463448
   PubMed Web of Science ®Google Scholar
• Ferrannini E Muscelli E Frascerra S Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients J Clin Invest 2014 124 2 499 508 24463454
   PubMed Web of Science ®Google Scholar
• Neschen S Scheerer M Seelig A Metformin supports the antidiabetic effect of a sodium glucose cotransporter 2 inhibitor by suppressing endogenous glucose production in diabetic mice Diabetes 2015 64 1 284 290 25071027
   PubMed Web of Science ®Google Scholar
• Balas B Baig MR Watson C The dipeptidyl peptidase IV inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single-dose administration in type 2 diabetic patients J Clin Endocrinol Metab 2007 92 4 1249 1255 17244786
   PubMed Web of Science ®Google Scholar
• Hansen L Iqbal N Ekholm E Cook W Hirshberg B Postprandial dynamics of plasma glucose, insulin, and glucagon in patients with type 2 diabetes treated with saxagliptin plus dapagliflozin add-on to metformin therapy Endocr Pract 2014 20 11 1187 1197 25370334
   PubMed Web of Science ®Google Scholar
• Raz I Mosenzon O Early insulinization to prevent diabetes progression Diabetes Care 2013 36 suppl 2 S190 S197 23882045
   PubMed Web of Science ®Google Scholar
• Scheen AJ Combined thiazolidinedione-insulin therapy: should we be concerned about safety? Drug Saf 2004 27 12 841 856 15366973
   PubMed Web of Science ®Google Scholar
• Buse JB Bergenstal RM Glass LC Use of twice-daily exenatide in basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial Ann Intern Med 2011 154 2 103 112 21138825
   PubMed Web of Science ®Google Scholar
• Ahmann A Rodbard HW Rosenstock J Efficacy and safety of liraglutide versus placebo added to basal insulin analogues (with or without metformin) in patients with type 2 diabetes: a randomized, placebo-controlled trial Diabetes Obes Metab 2015 17 11 1056 1064 26179619
   PubMed Web of Science ®Google Scholar
• Rosenstock J Fonseca VA Gross JL Advancing basal insulin replacement in type 2 diabetes inadequately controlled with insulin glargine plus oral agents: A comparison of adding albiglutide, a weekly GLP-1 receptor agonist, versus thrice-daily prandial insulin lispro Diabetes Care 2014 37 8 2317 2325 24898300
   PubMed Web of Science ®Google Scholar
• Barnett AH Charbonnel B Donovan M Fleming D Chen R Effect of saxagliptin as add-on therapy in patients with poorly controlled type 2 diabetes on insulin alone or insulin combined with metformin Curr Med Res Opin 2012 28 4 513 523 22313154
   PubMed Web of Science ®Google Scholar
• Yki-Jarvinen H Rosenstock J Duran-Garcia S Effects of adding linagliptin to basal insulin regimen for inadequately controlled type 2 diabetes: a ≥52-week randomized, double-blind study Diabetes Care 2013 36 12 3875 3881 24062327
   PubMed Web of Science ®Google Scholar
• Rosenstock J Rendell MS Gross JL Fleck PR Wilson CA Mekki Q Alogliptin added to insulin therapy in patients with type 2 diabetes reduces HbA(1C) without causing weight gain or increased hypoglycaemia Diabetes Obes Metab 2009 11 12 1145 1152 19758359
   PubMed Web of Science ®Google Scholar
• Vilsboll T Rosenstock J Yki-Jarvinen H Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes Diabetes Obes Metab 2010 12 2 167 177 20092585
   PubMed Web of Science ®Google Scholar
• Yoon NM Cavaghan MK Brunelle RL Roach P Exenatide added to insulin therapy: a retrospective review of clinical practice over two years in an academic endocrinology outpatient setting Clin Ther 2009 31 7 1511 1523 19695400
   PubMed Web of Science ®Google Scholar
• Seufert J Pegelow K Bramlage P Efficacy and safety of insulin glargine added to a fixed-dose combination of metformin and a dipeptidyl peptidase-4 inhibitor: results of the GOLD observational study Vasc Health Risk Manag 2013 9 711 717 24259985
   PubMedGoogle Scholar
• Rosenstock J Jelaska A Zeller C Kim G Broedl UC Woerle HJ Impact of empagliflozin added on to basal insulin in type 2 diabetes inadequately controlled on basal insulin: a 78-week randomized, double-blind, placebo-controlled trial Diabetes Obes Metab 2015 17 10 936 948 26040302
   PubMed Web of Science ®Google Scholar
• Wilding JP Woo V Soler NG Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trial Ann Intern Med 2012 156 6 405 415 22431673
   PubMed Web of Science ®Google Scholar
• Neal B Perkovic V de Zeeuw D Efficacy and safety of canagliflozin, an inhibitor of sodium-glucose cotransporter 2, when used in conjunction with insulin therapy in patients with type 2 diabetes Diabetes Care 2015 38 3 403 411 25468945
   PubMed Web of Science ®Google Scholar
• Damci T Emral R Svendsen AL Balkir T Vora J Lower risk of hypoglycaemia and greater odds for weight loss with initiation of insulin detemir compared with insulin glargine in Turkish patients with type 2 diabetes mellitus: local results of a multinational observational study BMC Endocr Disord 2014 14 61 25048824
   PubMed Web of Science ®Google Scholar
• Yale JF Damci T Kaiser M Initiation of once daily insulin detemir is not associated with weight gain in patients with type 2 diabetes mellitus: results from an observational study Diabetol Metab Syndr 2013 5 1 56 24499517
   PubMed Web of Science ®Google Scholar
• Vora J Combining incretin-based therapies with insulin: realizing the potential in type 2 diabetes Diabetes Care 2013 36 suppl 2 S226 S232 23882050
   PubMed Web of Science ®Google Scholar
• American Diabetes Association Fast Facts Data and Statistics about Diabetes 2015 Available from: http://professional.diabetes.org/ResourcesForProfessionals.aspx?cid=91777&loc=dorg-statistics Accessed March 23, 2015
   Google Scholar
• Gough SC Bode B Woo V Efficacy and safety of a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with its components given alone: results of a phase 3, open-label, randomised, 26-week, treat-to-target trial in insulin-naive patients with type 2 diabetes Lancet Diabetes Endocrinol 2014 2 11 885 893 25190523
   PubMed Web of Science ®Google Scholar
• Rosenstock J Ferrannini E Euglycemic diabetic ketoacidosis: a predictable, detectable, and preventable safety concern with SGLT2 inhibitors Diabetes Care 2015 38 9 1638 1642 26294774
   PubMed Web of Science ®Google Scholar
• FDA Drug Safety Communication: FDA revises labels of SGLT2 inhibitors for diabetes to include warnings about too much acid in the blood and serious urinary tract infections 2015 Available from: http://www.fda.gov/Drugs/DrugSafety/ucm475463.htm Accessed January 29, 2016
   Google Scholar
• Zinman B Wanner C Lachin JM Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes N Engl J Med 2015 373 22 2117 2128 26378978
   PubMed Web of Science ®Google Scholar
• Erondu N Desai M Ways K Meininger G Diabetic ketoacidosis and related events in the canagliflozin type 2 diabetes clinical program Diabetes Care 2015 38 9 1680 1686 26203064
   PubMed Web of Science ®Google Scholar
• AACE/ACE scientific and clinical review: association of SGLT2 inhibitors and DKA 2015 Available from: http://resources.aace.com/in-the-news/aaceace-scientific-and-clinical-review-association-sglt2-inhibitors-and-dka Accessed January 29, 2016
   Google Scholar
• Hsu PF Sung SH Cheng HM Association of clinical symptomatic hypoglycemia with cardiovascular events and total mortality in type 2 diabetes: a nationwide population-based study Diabetes Care 2013 36 4 894 900 23223349
   PubMed Web of Science ®Google Scholar
• ORIGIN Trial Investigators Gerstein HC Bosch J Basal insulin and cardiovascular and other outcomes in dysglycemia N Engl J Med 2012 367 4 319 328 22686416
   PubMed Web of Science ®Google Scholar
• UK Prospective Diabetes Study (UKPDS) Group Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes Lancet 1998 352 9131 837 853 9742976
   PubMed Web of Science ®Google Scholar
• Roumie CL Hung AM Greevy RA Comparative effectiveness of sulfonylurea and metformin monotherapy on cardiovascular events in type 2 diabetes mellitus: a cohort study Ann Intern Med 2012 157 9 601 610 23128859
   PubMed Web of Science ®Google Scholar
• Glucotrol® (glipizide tablets) [prescribing information] New York, NY Pfizer Inc 2010
   Google Scholar
• Micronase® (glyburide tablets) [full prescribing information] New York, NY Pfizer Inc 2010
   Google Scholar
• Amaryl® (glimepiride) [prescribing information] Bridgewater, NJ sanofiaventis 2013
   Google Scholar
• Kachroo S Kawabata H Colilla S Use of sulfonylureas in patients with multiple risk factors for CV disease or those with existing CV disease - CREST Study: are we following current ADA/EASD guidelines? [A1112] Paper presented at: 51st Annual Meeting, European Association for the Study of Diabetes September 14–18, 2015 Stockholm, Sweden
   Google Scholar
• Baxter C Das R Langerman H Increased risk of cardiovascular-related events associated with sulfonylureas compared to other antihyperglycaemic drugs: a Bayesian meta-analysis of survival data. [A128] Paper presented at: 51st Annual Meeting, European Association for the Study of Diabetes September 14–18, 2015 Stockholm, Sweden
   Google Scholar
• Berg B Wilke T Groth A Treatment characteristics and outcomes associated with sulphonylurea versus metformin therapy in incident type 2 diabetes mellitus patients: results of the German CREST study. [A130] Paper presented at: 51st Annual Meeting, European Association for the Study of Diabetes September 14–18, 2015 Stockholm, Sweden
   Google Scholar
• Cycloset® (bromocriptine mesylate) [prescribing information] Tiverton, RI VeroScience, LLC 2010
   Google Scholar
• Gaziano JM Cincotta AH O’Connor CM Randomized clinical trial of quick-release bromocriptine among patients with type 2 diabetes on overall safety and cardiovascular outcomes Diabetes Care 2010 33 7 1503 1508 20332352
   PubMed Web of Science ®Google Scholar
• Scirica BM Bhatt DL Braunwald E Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus N Engl J Med 2013 369 14 1317 1326 23992601
   PubMed Web of Science ®Google Scholar
• White WB Cannon CP Heller SR Alogliptin after acute coronary syndrome in patients with type 2 diabetes N Engl J Med 2013 369 14 1327 1335 23992602
   PubMed Web of Science ®Google Scholar
• Green JB Bethel MA Armstrong PW Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes N Engl J Med 2015 373 3 232 242 26052984
   PubMed Web of Science ®Google Scholar
• Zannad F Cannon C Cushman WC Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial Lancet 2015 385 9982 2067 2076 25765696
   PubMed Web of Science ®Google Scholar
• Fu AZ Johnston SS Ghannam A Tsai K Cappell K Fowler R Riehle E Cole AL Kalsekar I Sheehan J Association between hospitalization for heart failure and dipeptidyl peptidase 4 inhibitors in patients with type 2 diabetes: an observational study Diabetes Care 2016 39 5 726 734 26740636
   PubMed Web of Science ®Google Scholar
• Rosenstock J Marx N Kahn SE Cardiovascular outcome trials in type 2 diabetes and the sulphonylurea controversy: rationale for the active-comparator CAROLINA trial Diab Vasc Dis Res 2013 10 4 289 301 23449634
   PubMed Web of Science ®Google Scholar
• Cardiovascular and renal microvascular outcome study with linagliptin in patients with type 2 diabetes mellitus at high vascular risk (CARME-LINA) 2015 Available from: http://clinicaltrials.gov/ct2/show/NCT01897532?term=NCT01897532&rank=1 Accessed March 16, 2015
   Google Scholar
• Multicenter trial to evaluate the effect of dapagliflozin on the incidence of cardiovascular events (DECLARE-TIMI58) 2015 Available from: http://clinicaltrials.gov/ct2/show/NCT01730534?term=declare&rank=2 Accessed September 29, 2015
   Google Scholar
• Neal B Perkovic V de Zeeuw D Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)–a randomized placebo-controlled trial Am Heart J 2013 166 2 217 223.e11 23895803
   PubMed Web of Science ®Google Scholar
• American Diabetes Association First CVD outcome trial of a GLP-1 agonist finds no cardiac risk or benefit 2015 Available from: http://www.diabetes.org/newsroom/press-releases/2015/elixa.html?referrer=http://google.diabetes.org/search?site=Diabetes&client=diabetes&entqr=3&oe=ISO-8859-1&ie=ISO-8859-1&ud=1&proxystylesheet=diabetes&output=xml_no_dtd&proxyreload=1&q=ELIXA Accessed June 18, 2015
   Google Scholar
• Jiang Y Huang W Wang J Metformin plays a dual role in MIN6 pancreatic beta cell function through AMPK-dependent autophagy Int J Biol Sci 2014 10 3 268 277 24644425
   PubMed Web of Science ®Google Scholar
• Chao EC SGLT-2 inhibitors: a new mechanism for glycemic control Clin Diabetes 2014 32 1 4 11 26246672
   PubMedGoogle Scholar
• Barnett AH Redefining the role of thiazolidinediones in the management of type 2 diabetes Vasc Health Risk Manag 2009 5 1 141 151 19436665
   PubMedGoogle Scholar
• Green JB Feinglos MN Are sulfonylureas passe? Curr Diab Rep 2006 6 5 373 377 17076998
   PubMedGoogle Scholar
• Harrison LB Adams-Huet B Raskin P Lingvay I Beta-cell function preservation after 3.5 years of intensive diabetes therapy Diabetes Care 2012 35 7 1406 1412 22723578
   PubMed Web of Science ®Google Scholar